Security key
492327101
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS)
CUSIP: 492327101
Q3 2025 13F Holders as of 30 Sep 2025
- Security type / class
- Equity / Common Stock, $0.0001 par value per share
- Total 13F shares
- 35,272,212
- Total 13F value
- $558,014,186
- Share change
- -672,146
- Put/Call ratio
- 57%
- SEC-reported price per share
- $15.82
- Number of holders
- 151
- Value change
- -$7,638,925
- Number of buys
- 81
- Number of sells
- 54
- Shares outstanding
- 19,716,217
Holder snapshot
7 signals
Show 1 more signal
Security identity
1 source field
Report period
Q3 2025
Institutions
151
Top holders
10
KROS full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q4 2025
Previous quarter: Q2 2025
Keros Therapeutics, Inc. SEC filings
Keros Therapeutics, Inc. company facts
Broader feeds
Reporting periods
Holder history for CUSIP 492327101
Recent filing periods:
Ownership snapshot
Top reported holders of KROS - Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
ALKEON CAPITAL MANAGEMENT...
Disclosed value leader
ADAR1 Capital Management,...
Comparable rows
15/15
Latest evidence
30 Jun 2025
13D/G
13F
Lead comparable stake: 2.7%
13D/G row: ALKEON CAPITAL MANAGEMENT LLC
Showing 1-6 of 15 holder rows.
Quick read
ALKEON CAPITAL MANAGEMENT LLC leads the comparable SEC ownership view at 2.7%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Comparable ownership
Top 5
ALKEON CAPITAL MANAGEMENT LLC
2.7%
FMR LLC
1.7%
JPMORGAN CHASE & CO
0.2%
ADAR1 Capital Management, LLC
27%
BlackRock, Inc.
14%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| ALKEON CAPITAL MANAGEMENT LLC |
13D/G
13F
Company
|
2.7%
|
$15,645,210
1,101,000 shares
|
$0 | 31 Dec 2024 |
| FMR LLC |
13D/G
13F
Company
|
1.7%
|
$10,010,547
704,472 shares
|
$0 | 31 Jan 2025 |
| JPMORGAN CHASE & CO |
13D/G
13F
Company
|
0.2%
|
$1,617,141
113,803 shares
|
-$35,146,204 | 30 Apr 2025 |
| ADAR1 Capital Management, LLC |
13F
Company
|
27%
|
$71,946,674
5,389,264 shares
|
— | 30 Jun 2025 |
| BlackRock, Inc. |
13F
Company
|
14%
|
$36,480,511
2,732,623 shares
|
— | 30 Jun 2025 |
| Madison Avenue Partners, LP |
13F
Company
|
14%
|
$35,931,058
2,691,465 shares
|
— | 30 Jun 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q3 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
151
Shares
35,272,212
Rows available
151
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q3 2025 vs Q2 2025 Across Filers
Q2 2025 holders
134
Q3 2025 holders
151
Holder diff
17
| Investor | Q2 2025 Shares | Q3 2025 Shares | Share Diff | Share Chg % | Q2 2025 value | Q3 2025 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend